Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
remimazolam combined with remifentanil
The First People's Hospital of Lianyungang
Difficult or Failed Intubation
1 trial -
routine aspirin and heparin treatment
The First People's Hospital of Lianyungang
Acupuncture
1 trial -
salbutamol
The First People's Hospital of Lianyungang
Liver Transplantation
1 trial -
simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib
The First People's Hospital of Lianyungang
Gastrointestinal Stromal Tumors
1 trial -
sodium bicarbonate Ringer's solution
The First People's Hospital of Lianyungang
Hepatic Ischemia
1 trial -
solu medrol
The First People's Hospital of Lianyungang
Immunosuppression
1 trial -
standard-of-care imaging (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE PET/CT), 68Ga-MY6349 PET/CT
The First People's Hospital of Lianyungang
Tumor
1 trial -
tacrolimus
The First People's Hospital of Lianyungang
Renal Transplantation
1 trial -
telmisartan
The First People's Hospital of Lianyungang
Hypertension
1 trial -
the ginsenoside Rg3
The First People's Hospital of Lianyungang
Stage I Hepatocellular Carcinoma
1 trial -
thyroxine
The First People's Hospital of Lianyungang
Hypothyroidism
1 trial -
traditional chinese medicine Xuanfei-Zhike formula
The First People's Hospital of Lianyungang
Cough Variant Asthma
1 trial -
vats
The First People's Hospital of Lianyungang
NSCLC
1 trial -
xDRIVE Tumor Profiling
The First People's Hospital of Lianyungang
Cancer
1 trial -
zanubrutinib 160 mg BID orally
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma
1 trial -
zanubrutinib, bendamustine, and obinutuzumab
The First People's Hospital of Lianyungang
Follicular Lymphoma
1 trial -
zuojinwan
The First People's Hospital of Lianyungang
Functional Dyspepsia
1 trial -
Ξ³-globin reactivated autologous hematopoietic stem cells
The First People's Hospital of Lianyungang
Thalassemia Major
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources